the aid library

LIST OPTIONS

Filter

25569

WHO BioHub system: biosafety and biosecurity: criteria and operational modalities

World Health Organization WHO (2022) C_WHO

The WHO BioHub Biosafety & Biosecurity: criteria and operational modalities sets out the requirements to which laboratories wishing to receive ...iological materials as part of this international exchange system should abide, to ensure safe and secure operations. These provisions are in accordance with the recommendations of the WHO Laboratory Biosafety Manual 4th edition (LBM4), adopting an evidence- and risk-based approach to enable scalable and adaptable biosafety provisions and actions, proportionate to the assessed risk more

Download (190)

View PDF (378)

Product profile for a rapid test for diagnosis of Buruli ulcer at the primary health-care level

Diagnostics Technical Advisory Group (DTAG) World Health Organization WHO (2022) C_WHO

In 2013, WHO and the Foundation for Innovative New Diagnostics convened a meeting of Buruli ulcer experts in Geneva, Switzerland (9) at which two priority unmet needs in diagnosis were identified: a diagnostic test for early detection of ...uruli ulcer in symptomatic patients with sufficient positive predictive value to put patients on appropriate treatment; and a screening test at the primary health care or community level for symptomatic patients with ulcer In March 2018, they convened a global meeting with the aim of establishing an action plan to develop new diagnostic solutions for Buruli ulcer and to create a framework of collaboration to address unmet needs in diagnostics for the disease. The participants agreed to develop a target product profile (TPP) to address the need for a rapid diagnostic test for use at the primary health-care level. more

Download (158)

View PDF (345)

L'ulcère de buruli : reconnaître et agir : un manuel pour le personnel de santé

Organisation Mondiale de la Santé OMS (2011) C_WHO

/// ULCÈRE DE BURULIIV Les objectifs de ce document sont de contribuer à ce que l’ulcère de Buruli (infection à Mycobacterium ulcerans) soit mieux reconnu et d’inciter à intensifier les ef... more

External Link

Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions

Phillips, O.; J. Robert, K. Mohamed Abass et al. The Lancet Journal (2020) CC

The Lancet olume 395, ISSUE 10232, P1259-1267, April 18, 2020. Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans infection that damages the skin and subcutis. It is most ... more

External Link

Buruli ulcer: cured by 8 weeks of oral antibiotics?

Johnson, P.D.R. The Lancet Journal (2020) C1

Phillips and colleagues have shown that rifampicin combined with clarithromycin is non-inferior to RS8, and is safer. This much anticipated trial provides us with a high degree of confidence that an 8-week course of oral rifampicin and clarithromycin should now ...e the cornerstone of the treatment of Buruli ulcer everywhere. However, this finding does not mean that Buruli ulcer is cured at 8 weeks. more

Download (145)

View PDF (350)

Bodily autonomy and access to family planning are essential for responding to climate change

United Nations Population Fund UNFPA (2022) CC

Poster in english

Download (150)

View PDF (347)

Urban Ecosystem-based Adaptation: Regreening Cities to Takle Climate Change

UN Enivronemnt Programme UNEP (2022) CC

Briefing Note 8. Ecosystem-based adaptation (EbA) is a strategy for adapting to the adverse impacts of climate change by harnessing nature and the... more

External Link

Mapping the global distribution of Buruli ulcer: a systematic review with evidence consensus

Hope Simpson, Kebede Deribe, Earnest Njih Tabah, Adebayo Peters et al. The Lancet Journal (2019) CC

The Lancet Global Health Volume 7, ISSUE 7, e912-e922, July 01, 2019

Download (113)

View PDF (166)

First meeting of the network on Buruli ulcer PCR laboratories in the WHO African Region Centre Pasteur du Cameroon, Yaoundé, 21–24 October 2019

World Health Organization WHO (2020) CC

Research to develop point-of-care tests is in progress. Treatment of Buruli ulcer comprises 8 weeks of combined antibiotics (rifampicin and clarithromycin). Complementary therapies such as wound care, skin graft and prevention of disability are need... more

External Link

Buruli Ulcer: Mycobacterium Ulcerans Disease

Pluschke, G., and K. Röltgen Springer Nature (2017) CC

A major objective of this open access book is to summarize the current status of Buruli Ulcer (BU) research for the first time. It will identify ga... more

Report of a WHO–FIND meeting on diagnostics for Buruli ulcer

WHO Tecnical Advisory Group and FIND (2018) CC

The meeting was held from 26 to 27 March 2018 to review and discuss the following topics: Advances and challenges in the use of fTLC, and new approaches to detecting mycolactone using monoclonal antibodies (mAbs). The status of development of rapid diagnostic tests (RDTs) targeting the MUL... more

External Link

Clinical and Laboratory Diagnosis of Buruli Ulcer Disease: A Systematic Review

Sakyi; S.A.; Aboagye, S. Y.; Otchere, I. D. ; et al The Canadian Journal of Infectious Diseases & Medical Microbiology (2016) C1

Volume 2016 | Article ID 5310718 | https://doi.org/10.1155/2016/5310718. Buruli ulcer (BU) is a necrotizing cutaneous infection caused by Mycobacte... more

Download (270)

View PDF (234)

Ulcère de Buruli : guide de poche à l' intention des agents de santé communautaires

Organisation Mondiale de la Santé OMS (2005) C_WHO

Pocket guide

Download (527)

View PDF (262)

Guide des techniques de prélèvement d’échantillons pour la confirmation en laboratoire de l’infection à Mycobacterium ulcerans (‎ulcère de Buruli)‎

Organisation Mondiale de la Santé OMS (2008) C_WHO

Guide de techniques

External Link

Psychosis and bipolar disorders

World Health Organization WHO (2022) C_WHO

Evidence-based recommendations for management of psychosis and bipolar disorders in non-specialized health settings

Global Epidemiology of Buruli Ulcer, 2010–2017, and Analysis of 2014 WHO Programmatic Targets

Omansen, T.F.; A. Erbowor-Becksen, R. Yotsu, et al. Emerging Infectious Diseases (EID) Journal (2019) C_CDC

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 25, No. 12, December 2019 2183 Buruli ulcer is a neglected tropical disease caused by Myocobacterium ulcerans; it manifests as a skin lesio... more

Cotonou declaration on buruli ulcer
recommended

World Health Organization WHO (2009) CC

Cotonou Declaration oBuruli Ulcer Cotonou, Benin, 30 March 2009 Neglected tropical diseases kill, weaken or incapacitate millions of people every year, causing permanent physical suffering, social stigmatization and reduced productive capacity. ...uruli ulcer, one such disease, causes immense suffering and disabilities, especially among children. Delayed schooling and loss of productivity are considerable among the affected populations. These adverse consequences tend to aggravate poverty in affected communities. Globally, the disease has been reported in 30 countries. In WHO’s African Region, Buruli ulcer has been confirmed in 12 countries and is suspected in 10 others. Significant progress has been made in the past 10 years in knowledge of Buruli ulcer, investments in related research, control of the disease, and improvement of tools for case diagnosis and development of treatment protocols. Substantial achievements have been made in diagnosis, treatment, immunology and epidemiology. Despite these achievements, little is known about the exact mode of transmission of the disease, and there is no simple diagnostic test usable in the field. The use of antibiotics has revolutionized treatment and contributed to reducing the need for surgery by half. However, efforts are still needed to develop simple diagnostic tools usable in the field as well as disability prevention methods. The Global Buruli Ulcer Initiative has adopted the strategy recommended by WHO. The strategy is based on early diagnosis of the disease and the use of antibiotics for treatment upon the onset of the first signs by improving access to screening and case management at the most peripheral level of the health system. more